↓ Skip to main content

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects

Overview of attention for article published in Frontiers in oncology, February 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#21 of 22,758)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
36 news outlets
blogs
1 blog
twitter
17 X users

Citations

dimensions_citation
109 Dimensions

Readers on

mendeley
187 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Published in
Frontiers in oncology, February 2021
DOI 10.3389/fonc.2020.600573
Pubmed ID
Authors

Remy Thomas, Ghaneya Al-Khadairi, Julie Decock

Abstract

Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient's own immune cells to kill tumors and revolutionizing cancer treatment in a variety of cancers. Although breast cancer was historically believed to be immunologically silent, treatment with immune checkpoint inhibitors has been shown to induce modest responses in metastatic breast cancer. Given the inherent heterogeneity of breast tumors, this raised the question whether certain breast tumors might benefit more from immune-based interventions and which cancer cell-intrinsic and/or microenvironmental factors define the likelihood of inducing a potent and durable anti-tumor immune response. In this review, we will focus on triple negative breast cancer as immunogenic breast cancer subtype, and specifically discuss the relevance of tumor mutational burden, the plethora and diversity of tumor infiltrating immune cells in addition to the immunoscore, the presence of immune checkpoint expression, and the microbiome in defining immune checkpoint blockade response. We will highlight the current immune checkpoint inhibitor treatment options, either as monotherapy or in combination with standard-of-care treatment modalities such as chemotherapy and targeted therapy. In addition, we will look into the potential of immunotherapy-based combination strategies using immune checkpoint inhibitors to enhance both innate and adaptive immune responses, or to establish a more immune favorable environment for cancer vaccines. Finally, the review will address the need for unambiguous predictive biomarkers as one of the main challenges of immune checkpoint blockade. To conclude, the potential of immune checkpoint blockade for triple negative breast cancer treatment could be enhanced by exploration of aforementioned factors and treatment strategies thereby providing promising future prospects.

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 187 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 187 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 28 15%
Researcher 21 11%
Student > Master 16 9%
Student > Bachelor 13 7%
Student > Doctoral Student 6 3%
Other 20 11%
Unknown 83 44%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 32 17%
Medicine and Dentistry 17 9%
Agricultural and Biological Sciences 11 6%
Pharmacology, Toxicology and Pharmaceutical Science 9 5%
Immunology and Microbiology 8 4%
Other 22 12%
Unknown 88 47%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 284. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2023.
All research outputs
#126,029
of 25,655,374 outputs
Outputs from Frontiers in oncology
#21
of 22,758 outputs
Outputs of similar age
#3,981
of 452,837 outputs
Outputs of similar age from Frontiers in oncology
#2
of 939 outputs
Altmetric has tracked 25,655,374 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,758 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 452,837 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 939 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.